对“降低美国药价30%-80%行政令”的一些看法

Core Viewpoint - The article discusses the potential impact of Trump's announcement regarding the "Most Favored Nation's Policy" on the U.S. pharmaceutical pricing system, suggesting a need for observation to determine whether this represents a systemic shift or a temporary disruption [1][2]. Group 1: U.S. Pharmaceutical Pricing System - The U.S. pharmaceutical pricing is notably higher due to a highly market-driven system with minimal government intervention compared to other countries [2]. - The presence of commercial insurance in the U.S. benefits from high drug prices, as these companies profit from rebates negotiated with pharmaceutical firms, leading to a preference for maintaining elevated nominal prices [2]. Group 2: Potential Outcomes of Policy Changes - One scenario suggests that if Trump successfully drives deep reforms in the U.S. healthcare system, it could have profound implications for both the U.S. and global pharmaceutical industries [3][4]. - However, without the establishment of a regulatory body akin to a national pricing authority, systemic changes are unlikely, and any reforms may face significant opposition from the pharmaceutical and insurance sectors [4][6]. Group 3: Impact on Biotech Innovation - The current high pricing environment supports innovation in the U.S. biotech sector; any forced reduction in profit margins could diminish the incentive for high-risk investments and innovation [7]. - A decrease in profit expectations may lead U.S. pharmaceutical companies to adopt more cost-effective strategies, potentially reshaping the biotech landscape and suppressing industry growth for an extended period [7].